Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 21, 2026, 7:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–3 of 3 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: BRCA1-Associated Protein-1 (BAP1) Mutations Clear all

Suspended Phase 2 Interventional

Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma

NCT05960773

View directory record Official record

Conditions: Mesothelioma, Malignant Mesothelioma (MM), Early-stage Mesothelioma, Subclinical Mesothelioma, BRCA1-Associated Protein-1 (BAP1) Mutations, Early-stage BAP1-associated Malignancies
Interventions: Decitabine/cedazuridine; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years

Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Source: ClinicalTrials.gov public record

Updated May 3, 2026 · Synced May 21, 2026, 7:23 PM EDT

Withdrawn Phase 2 Interventional

Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma

NCT06654050

View directory record Official record

Conditions: Mesothelioma, Malignant Mesothelioma (MM), Early-stage Mesothelioma, Subclinical Mesothelioma, BRCA1-Associated Protein-1 (BAP1) Mutations, Early-stage BAP1-associated Malignancies
Interventions: alrizomadlin; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years

Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Source: ClinicalTrials.gov public record

Updated Mar 16, 2026 · Synced May 21, 2026, 7:23 PM EDT

Recruiting No phase listed Observational Accepts healthy volunteers

Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome

NCT04431024

View directory record Official record

Conditions: Familial Cancer, BRCA1-Associated Protein-1 (BAP1) Mutations, Tumor Predisposition Syndrome (TPDS), Mesothelioma
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 30 Years to 120 Years

Enrollment: 800 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2038
U.S. locations: 1
States / cities: Bethesda, Maryland

Source: ClinicalTrials.gov public record

Updated Apr 30, 2026 · Synced May 21, 2026, 7:23 PM EDT